Donor lymphocyte infusion combined with azacitidine after allogeneic HSCT in pediatric AML: a single-center retrospective analysis
Azacitidine combined with DLI is feasible and safe in pediatric AML after HSCT, particularly when applied prophylactically or preemptively to restore donor chimerism or eradicate MRD. Therapeutic use in overt relapse remains challenging and provides limited benefit. Prospective multicenter studies are needed to define optimal timing, dosing, and combination strategies for integrating azacitidine with DLI in this high-risk pediatric population.
Authors
- Cristina Jercan (ORCID: https://orcid.org/0000-0001-9039-5859)
- Andrei Coliţă
- Anca Coliţă (ORCID: https://orcid.org/0000-0001-6031-8190)
- Andra Marcu (ORCID: https://orcid.org/0000-0003-3706-6620)
- Ileana Constantinescu
- Delia Codruţa Popa (ORCID: https://orcid.org/0000-0002-7638-3285)
- Ana Bica
- Andreea Nicoleta Serbanica
- Irina Avramescu
- Iuliana Iordan
- Alexandra Mihaela Ichim
- Matei Colita
Institutions
- Carol Davila University of Medicine and Pharmacy (RO)
- Clinical Emergency Hospital Bucharest (RO)
- Institutul Clinic Fundeni (RO)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.3389/fphar.2025.1727492
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00